VEGFA and hepatocellular carcinoma: Data from the SHARP trial alone evaluating sorafenib as front-line in HCC revealed that vascular invasion and high levels of specific proteins such as angiopoietin 2 (Ang2), alpha-feto protein (AFP), and vascular endothelial growth factor (VEGF) were independent predictors of poor OS [38].